Abstract
Meropenem-vaborbactam is a new beta-lactam/beta-lactamase inhibitor combination that combines a carbapenem antibiotic with a first-in-class, boronic acid pharmacophore, serine beta-lactamase inhibitor which has potent inhibitory activity against class A carbapenemases, especially Klebsiella pneumoniae carbapenemases (KPC), in addition to other class A and class C beta-lactamases. The US Food and Drug Administration has recently approved meropenem-vaborbactam for the treatment of adult patients with complicated urinary tract infections including acute pyelonephritis. Areas covered: A PubMed search was performed to gather the most current and relevant articles regarding meropenem-vaborbactam. In this review the authors discuss the chemistry, mechanism of action, pharmacokinetics, pharmacodynamics, antimicrobial spectrum, and efficacy and safety of meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis Expert opinion: Although meropenem-vaborbactam is approved for treatment for complicated urinary tract infections including acute pyelonephritis, it is unlikely, at this point, to be utilized widely beyond cases that are caused by KPC-producing Enterobacteriaceae. It may also b...Continue Reading
References
May 1, 1999·Antimicrobial Agents and Chemotherapy·M P Mingeot-Leclercq, P M Tulkens
Aug 10, 2000·The Journal of Antimicrobial Chemotherapy·W GoettschA J de Neeling
Feb 15, 2001·The Journal of Infectious Diseases·W E Stamm, S R Norrby
Apr 18, 2008·Drugs·Claudine M BaldwinSusan J Keam
Jul 16, 2008·Clinical Microbiology Reviews·David LandmanJohn Quale
Sep 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David P Nicolau
Feb 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kalpana GuptaUNKNOWN European Society for Microbiology and Infectious Diseases
Aug 24, 2011·Antimicrobial Agents and Chemotherapy·Krisztina M Papp-WallaceRobert A Bonomo
Mar 16, 2012·The New England Journal of Medicine·Thomas M Hooton
Apr 24, 2012·Chemical Reviews·Reem SmoumMorris Srebnik
Mar 18, 2015·Journal of Medicinal Chemistry·Scott J HeckerMichael N Dudley
Apr 9, 2015·Nature Reviews. Microbiology·Ana L Flores-MirelesScott J Hultgren
Jun 3, 2015·Antimicrobial Agents and Chemotherapy·Amabel LapueblaDavid Landman
Jul 7, 2016·Antimicrobial Agents and Chemotherapy·Mariana CastanheiraRonald N Jones
Aug 17, 2016·Antimicrobial Agents and Chemotherapy·David C GriffithMichael N Dudley
Sep 7, 2016·Virulence·David van Duin, Yohei Doi
Oct 8, 2016·Postgraduate Medicine·Mazen S BaderAnnie A Brooks
May 30, 2017·Brazilian Journal of Microbiology : [publication of the Brazilian Society for Microbiology]·Daniele Zendrini RechenchoskiEliana Carolina Vespero
Jun 28, 2017·Antimicrobial Agents and Chemotherapy·Mariana CastanheiraRobert K Flamm
Aug 30, 2017·Antimicrobial Agents and Chemotherapy·Olga LomovskayaMichael N Dudley
Nov 1, 2017·Antimicrobial Agents and Chemotherapy·Meredith A HackelDaniel F Sahm
Dec 13, 2017·ACS Infectious Diseases·Karen Bush
Feb 28, 2018·JAMA : the Journal of the American Medical Association·Keith S KayeEvangelos J Giamarellos-Bourboulis
Mar 8, 2018·The Journal of Antimicrobial Chemotherapy·Peter M HawkeyA Peter R Wilson
Apr 26, 2018·Future Microbiology·Twisha S PatelKeith S Kaye
Citations
Sep 11, 2019·Expert Opinion on Pharmacotherapy·Krisztina M Papp-Wallace
Dec 27, 2019·Biomedit︠s︡inskai︠a︡ khimii︠a︡·D A BeshnovaA M Egorov
Dec 15, 2019·Biomolecules·Alexey EgorovAlexander Veselovsky
Oct 22, 2020·Research : a Science Partner Journal·Zifang ShangWei Huang
Nov 6, 2020·The Journal of Antimicrobial Chemotherapy·Nicola OoiVictoria J Savage
Feb 15, 2021·International Journal of Biological Macromolecules·Sourya BhattacharyaSaugata Hazra